

# Correction of RT–qPCR data for genomic DNA-derived signals with ValidPrime

Henrik Laurell<sup>1,\*</sup>, Jason S. Iacovoni<sup>1</sup>, Anne Abot<sup>1</sup>, David Svec<sup>2,3</sup>, Jean-José Maoret<sup>1,4</sup>, Jean-François Arnal<sup>1,5</sup> and Mikael Kubista<sup>2,3</sup>

<sup>1</sup>Inserm/Université Paul Sabatier UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), BP84225, 31432 Toulouse cedex 4, France, <sup>2</sup>Laboratory of Gene Expression, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, <sup>3</sup>TATAA Biocenter AB, Göteborg, Sweden, <sup>4</sup>Plateforme GeT (Génome et Transcriptome) du Génomopole Toulouse, Toulouse, France and <sup>5</sup>Faculté de Médecine, Université de Toulouse III and CHU de Toulouse

Received September 17, 2011; Revised November 21, 2011; Accepted December 5, 2011

## ABSTRACT

Genomic DNA (gDNA) contamination is an inherent problem during RNA purification that can lead to non-specific amplification and aberrant results in reverse transcription quantitative PCR (RT–qPCR). Currently, there is no alternative to RT(–) controls to evaluate the impact of the gDNA background on RT–PCR data. We propose a novel method (ValidPrime) that is more accurate than traditional RT(–) controls to test qPCR assays with respect to their sensitivity toward gDNA. ValidPrime measures the gDNA contribution using an optimized gDNA-specific ValidPrime assay (VPA) and gDNA reference sample(s). The VPA, targeting a non-transcribed locus, is used to measure the gDNA contents in RT(+) samples and the gDNA reference is used to normalize for GOI-specific differences in gDNA sensitivity. We demonstrate that the RNA-derived component of the signal can be accurately estimated and deduced from the total signal. ValidPrime corrects with high precision for both exogenous (spiked) and endogenous gDNA, contributing ~60% of the total signal, whereas substantially reducing the number of required qPCR control reactions. In conclusion, ValidPrime offers a cost-efficient alternative to RT(–) controls and accurately corrects for signals derived from gDNA in RT–qPCR.

## INTRODUCTION

Accurate gene expression analysis by reverse transcription (RT) quantitative PCR (qPCR) requires assays with high specificity for the target cDNA/reference gene, collectively

referred to herein as the Gene-Of-Interest (GOI). It is important to have negligible signal contribution from experimental artifacts, such as primer–dimers and contaminating genomic DNA (gDNA). Traditionally, primer–dimer formation is tested using a ‘no template control’ (NTC) and gDNA contamination levels are measured with RT(–) controls [which differ from regular RT(+) reactions in that no reverse transcriptase is added]. Contamination of gDNA is an inherent problem during RNA purification due to the similar physicochemical properties of RNA and DNA. Since gDNA contamination levels are frequently not uniform between samples (1) and the sensitivity toward gDNA differs greatly between GOI assays, RT(–) controls are needed for each sample/assay pair, which substantially adds to the cost and labor in RT–qPCR profiling studies. A difference of at least five quantification cycles ( $C_q$ ) between RT(+) and RT(–) reactions indicates that <3% of the total signal originates from gDNA, and is commonly used as limit to ensure accurate estimation of GOI expression. Smaller differences typically call for DNase treatment of samples.

The accuracy of gDNA background estimation, as measured with RT(–) reactions, is compromised due to the fact that GOI assays, designed to amplify target transcripts, are used even though they are not optimized for gDNA amplification. Furthermore, intrinsic characteristics of RT(–)–qPCRs that influence the result of the correction, such as amplification efficiencies, are difficult to assess. In addition, as proposed theoretically (2) and shown experimentally (3,4), a low initial number of target molecules leads to a large variability between replicates, mainly due to stochastic effects. All together, this explains the low reproducibility frequently observed in RT(–) reactions.

The qPCR assays can be either gDNA sensitive or insensitive. Whereas qPCR assays can be designed to be

\*To whom correspondence should be addressed. Tel: +33 561323128; Fax: +33 561322141; Email: henrik.laurell@inserm.fr

gDNA insensitive, such as those designed to target exons flanking a long intron or with primers that cross exon–exon junctions, qPCR assays for single-exon genes will readily amplify contaminating gDNA. The gDNA background signal is even further amplified in the presence of multiple genomic copies or pseudogenes. The latter are particularly troublesome since they may originate from retrotransposons without introns that are amplified even with intron-spanning assays. Thus, there exists both variation in the degree of contamination between samples and large differences between assays in terms of their sensitivity to gDNA. Therefore, general methods of controlling and correcting for gDNA contamination are essential for accurate measurements of gene expression.

As an alternative to RT(–) reactions, we have developed a procedure that determines the impact of the gDNA contamination on the measured signal much more accurately and allows validation of qPCR primers with respect to their sensitivity toward gDNA. We show in proof-of-principle experiments that efficient background correction can be performed with gDNA contamination representing ~60% of the total signal.

## MATERIALS AND METHODS

### Samples

All samples were from mouse (C57Bl/6J) tissues (kidney, liver, adipose tissue, uterus, peritoneal macrophages). All experimental procedures involving animals were performed in accordance with the principles and guidelines established by the National Institute of Medical Research (Inserm) and were approved by the local Animal Care and Use Committee. Prior to sampling, mice were anesthetized by intraperitoneal injection of ketamine (100 mg kg<sup>-1</sup>) and xylazine (10 mg kg<sup>-1</sup>). Tissues were snap-frozen in liquid nitrogen and stored at –80°C. Isolation of peritoneal macrophages has been described elsewhere (5). Macrophages were in some cases treated with 20 ng/ml LPS *ex vivo* for 4 h prior to RNA extraction.

### DNA extraction

C57Bl/6J mouse gDNA was extracted from whole blood using the PerfectPure DNA Blood Cell Kit, according to the recommended protocol (5'PRIME GmbH, Hamburg, Germany). Good results were also obtained with gDNA purified from mouse tails by phenol/chloroform extraction after Proteinase K digestion (6). The DNA concentration was determined spectroscopically (NanoDrop).

### RNA extraction

Total RNA was extracted using a double purification protocol. Briefly, Trireagent (Sigma-Aldrich, St Louis, MI, USA) was added to the frozen tissue sample, which was homogenized in a Precellys 24 homogenizer (Bertin Technologies, France). After the extraction step, the supernatant was gently mixed with 1 Vol 70% ethanol and applied on a total RNA miniprep Genelute column, where it was washed and eluted following the instructions from the manufacturer (Sigma-Aldrich). The integrity and

quality of the RNA was tested by capillary micro-electrophoresis [MultiNA (Shimadzu) or Experion (BioRad)] and spectroscopically (NanoDrop). A fraction of the RNA was DNase treated using the DNAfree kit from Ambion. To avoid inhibition of the reverse transcriptase, the volume of DNase treated RNA did not exceed 25% of the total volume during RT.

### RT

Total RNA (1.0–5.0 µg) was reverse transcribed in 20–50 µl using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using random hexamers. The reaction mixture was incubated for 10 min at 25°C, 120 min at 37°C and finally for 5 min at 85°C, according to instructions from the manufacturer (Applied Biosystems). RT reactions were diluted 5–10-fold prior to qPCR.

### Real-time qPCR

*Conventional qPCR.* All reactions (except when indicated) were performed in duplicate 10 µl volumes using 20 ng reverse transcribed total RNA in a StepOnePlus system (Applied Biosystems) with the SsoFast EvaGreen Supermix (BioRad) and an assay concentration of 300 nM using the cycling parameters: 95°C (20 s) followed by 40 cycles at 95°C (3 s) and 60°C (20 s). Melting curve analysis: 95°C (15 s); 60°C (60 s) and a progressive increase up to 95°C (0.5°C/min). Analysis of the data was performed with the StepOne software v.2.2.

*High-throughput qPCR.* The 96.96 Dynamic Arrays for the microfluidic BioMark™ system (Fluidigm Corporation, CA, USA) (7) were used to study gene expression in 6.5 ng cDNA from mouse peritoneal macrophages or mouse uterus, as described below.

*Specific target amplification.* Pre-amplification of cDNA (produced from 25 to 65 ng of total RNA) was performed in the StepOnePlus cycler (Applied Biosystems) [at 95°C for 10 min activation step followed by 14 cycles: 95°C, (15 s), 60°C, (4 min)] in a total volume of 5 µl in the presence of all primers at a concentration of 50 nM. After pre-amplification, 20 µl Low EDTA TE Buffer [10 mM Tris pH8 (Ambion), 0.1 mM EDTA pH8 (Sigma)] was added to each sample.

*Sample Mix for BioMark analysis.* The pre-sample mix contained 66.7% 2X Taqman® Gene Expression Master Mix (Applied Biosystems), 6.67% 20X DNA Binding Dye Sample Loading Reagent (Fluidigm), 6.67% 20X EvaGreen™ (Biotium), 20% Low EDTA TE Buffer. Sample mix was obtained by mixing 5.6 µl of the pre-sample mix with 1.9 µl of diluted cDNA.

*Assay Mix.* A quantity of 3.8 µl 2X Assay Loading Reagent (Fluidigm) and 1.9 µl Low EDTA TE Buffer were mixed with 1.9 µl of primers (20 µM of each forward and reverse primer).

*qPCR conditions.* After priming of the 96.96 Dynamic Array in the NanoFlex™ 4-Integrated Fluidic Circuits

(IFC) Controller (Fluidigm), 5 µl of each sample and 5 µl of each assay mix were added to dedicated wells. The dynamic array was then placed again in the IFC Controller for loading and mixing under the following conditions: 50°C (2 min); 70°C (30 min) and 25°C (10 min). The loaded Dynamic Array was transferred to the BioMark™ real-time PCR instrument. After initial incubation at 50°C (2 min) and activation of the Hotstart enzyme at 95°C (10 min) cycling was performed using 95°C (15 s), and 60°C (1 min) for 35 cycles, followed by melting curve analysis (1°C/3 s).

**Data analysis.** Initial data analysis was performed with the Fluidigm real-time PCR analysis software v. 3.0.2 with linear derivative baseline correction and a quality correction set to 0.65.

### Design of ValidPrime assays

Intergenic regions in the mouse genome with no known transcriptional activity were selected using the UCSC genome browser (<http://genome.ucsc.edu/>). In total, 30 assays targeting 10 different regions on 5 chromosomes were designed using PrimerBlast (NCBI). Amplification efficiencies were determined with a dilution series of gDNA (50–5000 haploid genome copies). PCR products were analyzed for purity by recording melting curves and by capillary micro-electrophoresis (MultiNA, Shimadzu), leading to the selection of five assays for limit of detection (LOD) and limit of quantification (LOQ) determination.

### LOD and LOQ determination of ValidPrime assays

Five assays were selected for determination of LOD and LOQ using eight concentrations (0, 1, 2, 4, 8, 16, 32, 64 copies) in the presence of 50 ng/µl carrier yeast tRNA (Roche Molecular Biochemicals). Sequence information for the two best candidates, in terms of sensitivity and specificity, is provided in [Supplementary Table S1](#). Except when stated otherwise, mVPA1 was used as the VPA.

### GOI assay design and validation

Non-commercial GOI assays were either taken from previously published studies (5,8,9) or designed with the Primer-BLAST utility at NCBI. Sequences are reported in [Supplementary Table S1](#). Specificity was evaluated by BLAST (mouse RefSeq database) during design and by *in silico* PCR (UCSC Genome Browser). Amplification efficiencies were evaluated in the BioMark system on dilutions series of both cDNA and gDNA.

### Exogenous gDNA spiking experiments

Quantities ranging from 50 to 5000 haploid genome copies (corresponding to 0.15–15 ng gDNA) or water were added to 20 ng (StepOnePlus) or 6.5 ng (BioMark) cDNA. Non-spiked samples had low, but detectable gDNA levels. For the BioMark runs, the gDNA was added prior to the pre-amplification step. Genome copy number calculations were based on the NCBI m37 assembly of the C57Bl/6 mouse genome (2 716 965 481 bp) assuming an average molecular weight of 660 g/mol/bp.

The mass of a haploid mouse genome was thus estimated to be 2.98 pg.

### Data analysis and statistics

$Cq_{\text{DNA}}$ ,  $Cq_{\text{RNA}}$  and %DNA were calculated using the gh-validprime software (<https://code.google.com/p/gh-validprime>). The GenEx software (v.5.3, [www.multiD.se](http://www.multiD.se)) was used for one-way ANOVA analysis and to calculate LOD. Data are presented as mean ± SD.

## RESULTS

### The ValidPrime method

We developed ValidPrime to estimate and correct for gDNA contribution in RT(+)-qPCR measurements in a more reliable manner than that afforded by RT(-) controls. We refer to the signal measured in an RT(+)-qPCR as  $Cq_{\text{NA}}$  (NA : Nucleic Acids) [Equation (1)], indicating contributions from RNA ( $Cq_{\text{RNA}}$ ) as well as gDNA ( $Cq_{\text{DNA}}$ ) as shown in Equation (2), expressed in relative quantities.

$$Cq_{\text{RT}+} = Cq_{\text{NA}} \quad (1)$$

$$2^{-Cq_{\text{NA}}} = 2^{-Cq_{\text{RNA}}} + 2^{-Cq_{\text{DNA}}} \quad (2)$$

Traditionally, determination of the RNA component using RT(-) controls would be achieved using Equation (3). However, as detailed in the introduction, low reproducibility and other factors detract from the accuracy of this approach. We propose that Equation (4), derived in [Supplementary Figure S1A](#), provides an accurate solution provided that  $Cq_{\text{DNA}}$  is estimated using ValidPrime, Equation (5), in which GOI refers to any transcribed ‘GOI’, including reference genes, studied in a RT-qPCR experiment.  $Cq_{\text{RNA}}$  and  $Cq_{\text{DNA}}$  refer to the signal contribution derived from RNA (cDNA) and DNA (gDNA), respectively, in a RT+ sample.

$$Cq_{\text{RNA}} = -\log_2(2^{-Cq_{\text{RT}+}} - 2^{-Cq_{\text{RT}-}}) \quad (3)$$

$$Cq_{\text{RNA}} = -\log_2(2^{-Cq_{\text{NA}}} - 2^{-Cq_{\text{DNA}}}) \quad (4)$$

$$Cq_{\text{DNA}} = Cq_{\text{Sample}}^{\text{VPA}} + Cq_{\text{gDNA}}^{\text{GOI}} - Cq_{\text{gDNA}}^{\text{VPA}} \quad (5)$$

For the determination of  $Cq_{\text{DNA}}$  [Equation (5)], the gDNA contamination level in a RT(+) sample (referred to as ‘Sample’) is measured with a gDNA-specific ValidPrime assay (VPA) ( $Cq_{\text{sample}}^{\text{VPA}}$ ). The VPA targets a non-transcribed locus present in one copy per normal haploid genome. However, since the gDNA sensitivity can be highly variable between GOI assays, the capacity of the GOI assay to amplify gDNA is compared with that of the VPA. In ValidPrime, this difference is tested on purified gDNA, yielding the delta  $Cq$  component in Equation (5) ( $Cq_{\text{gDNA}}^{\text{GOI}} - Cq_{\text{gDNA}}^{\text{VPA}}$ ). Despite a formulaic resemblance to the  $\Delta\Delta Ct$  equation developed by Livak and Schmittgen (10), these calculations are distinct ([Supplementary Figure S1B](#)).

Figure 1 depicts a typical grid of qPCR data including the required controls for ValidPrime estimation of  $Cq_{\text{DNA}}$  and the subsequent correction of  $Cq_{\text{NA}}$  into  $Cq_{\text{RNA}}$ . Apart

$$2^{-Cq_{NA}} = 2^{-Cq_{RNA}} + 2^{-Cq_{DNA}} \quad (Eq 2)$$

$Cq_{NA}$	GOI 1	GOI 2	GOI 3	VPA
Sample 1	27.22	25.78	28.67	29.02
Sample 2	26.73	25.54	28.02	26.97
Sample 3	26.42	25.31	27.68	26.34
gDNA	29.62	29.41	30.60	28.61

$$Cq_{DNA} = Cq_{Sample}^{VPA} + Cq_{gDNA}^{GOI} - Cq_{gDNA}^{VPA} \quad (Eq 5)$$

$$Cq_{DNA}^{GOI1} = 29.02 + 29.62 - 28.61 = 30.03$$

$$Cq_{RNA} = -\log_2(2^{-Cq_{NA}} - 2^{-Cq_{DNA}}) \quad (Eq 3)$$

$$Cq_{NA}^{GOI1} = 27.22$$

$$Cq_{RNA}^{GOI1} = -\log_2(2^{-27.22} - 2^{-30.03}) = 27.44$$

$$\%DNA = (2^{-Cq_{DNA}} / 2^{-Cq_{NA}}) * 100 \quad (Eq 6)$$

$$\%DNA^{GOI1} = (2^{-30.03} / 2^{-27.22}) * 100 = 14.3 \%$$

**Figure 1.** ValidPrime: principles and exemplifying equations. ValidPrime uses the annotation  $Cq_{NA}$  for the signal measured in a (RT+) qPCR sample, to which both Nucleic Acids, RNA and DNA contribute, corresponding to  $Cq_{RNA}$  and  $Cq_{DNA}$  [Equation (2)]. The grid shows an example of an experimental design with 3 RT+ samples and 3 GOI assays, plus the controls required for the ValidPrime estimation of  $Cq_{DNA}$  and the subsequent correction of  $Cq_{NA}$  to obtain  $Cq_{RNA}$ . The term GOI is used in ValidPrime for both target transcripts and reference genes, since the calculations are independent of the gene type. The VPA column contains the data obtained with the VPA and the gDNA row contains measurements using purified gDNA as a sample. The equations under the grid illustrate the determination of  $Cq_{DNA}$ ,  $Cq_{RNA}$  and %DNA for GOI 1 in sample 1 according to the color code in the grid.

from the GOI assays, that are specific for each study, the VPA has been added among the assays. In addition to samples 1–3, which correspond to any RT+ samples in qPCR study, one or several gDNA samples are added in the experimental design. The equations under the grid exemplify the calculations for GOI 1 in Sample 1. The gDNA contribution can also be expressed as a percentage of relative quantities [Equation (6)].

$$\%DNA = \left( \frac{2^{-Cq_{DNA}}}{2^{-Cq_{NA}}} \right) \times 100 \quad (6)$$

### Assay validation

In order to determine the accuracy of the ValidPrime method, we first designed and characterized candidate VPAs. Among 30 candidates from 10 different regions on five chromosomes, 26 amplified gDNA with efficiencies between 90 and 110%. Among the tested assays, mVPA1 (amplifying an 87-bp sequence in the qB region of chromosome 1) and mVPA5 (amplifying an 87-bp sequence in the qF region of chromosome 5) had the best characteristics in terms of sensitivity and specificity. LOD was 3.2 copies for mVPA1 (GenEx; Cut-off  $Cq$  37;

95% CI; mean of two determinations) and 3.7 copies for mVPA5 (GenEx; Cut-off  $Cq$  37; 95% CI) and the LOQ (SD < 45%) was 4 copies for both assays (Supplementary Figure S2). In four out of eight NTC reactions, a signal ( $Cq$   $38.1 \pm 0.9$ ) was detected with the mVPA5 assay, indicating formation of primer–dimers. However, the primer–dimer product was never observed in samples containing gDNA, as evaluated by melting curve analyses and by capillary micro-electrophoresis (MultiNA, Shimadzu).


Efficiency analysis for GOI assays was performed in the BioMark system. No amplification was observed in the NTC controls, except for Sprr2f ( $Cq$  28.6), which was 10 cycles above the  $Cq$  measured in the sample with the lowest Sprr2f expression ( $Cq$  18.5) and thus, far more than the proposed accepted minimal difference of five cycles between NTC and RT(+) sample (11,12). The generally low  $Cq$  values obtained with the BioMark system are explained by the 14-cycle pre-amplification step used in this protocol. The amplification efficiency was similar between assays as measured with a cDNA dilution series ( $95.5 \pm 6.1\%$ ; mean  $R^2$ : 0.9932) and a gDNA dilution series for gDNA-sensitive assays ( $100.4 \pm 7.7\%$ ; mean  $R^2$ : 0.9962) (data not shown). All RNA samples used in the study had A260/A280 ratios between 1.9 and 2.0 (mean: 1.97); A260/A230 between 1.5 and 2.5 (mean: 2.13) and A260/A270 above 1.17 (mean: 1.23), where the latter tests for phenol contamination.

### Equivalence between $Cq_{DNA}$ estimated with ValidPrime and RT(–) controls

We next verified that the  $Cq_{DNA}$  values calculated with ValidPrime agree with those measured directly in RT(–)–qPCRs. Since a direct comparison is difficult, due to the poor reproducibility of RT(–) controls (see above), the following test was performed: RT(+) and RT(–) samples from two different tissues were spiked with 0.30 ng of gDNA (approximately 100 haploid genome copies) and measured using three gDNA-sensitive GOI assays. The data in Figure 2 are ratios of relative quantities (RQ) between either the total signal ( $Cq_{NA}$ ) in RT(+) reactions or the corresponding  $Cq_{DNA}$  calculated by ValidPrime over the RQ in RT(–) reactions. As shown, tissue-dependent differences in the expression levels of the three target genes were observed [from 1.8- to 27-fold compared with RT(–) samples]. Independent of the expression level, the estimation by ValidPrime of the gDNA-derived signal levels ( $Cq_{DNA}$ ) in RT(+) samples was in excellent agreement with the data from RT(–) samples, with the ratio of the relative quantities ( $1.20 \pm 0.29$ ) close to the theoretically expected value of 1.

### Calculation of $Cq_{RNA}$ in RT(+) samples through the correction of signals derived from exogenously added gDNA

Given the good correlation between ValidPrime estimation of  $Cq_{DNA}$  and RT(–) measurements, we next tested the accuracy of the calculation of the RNA-derived component  $Cq_{RNA}$  in RT(+) samples using Equation (4). In a first set of experiments, different amounts of gDNA were



**Figure 2.** Equivalence between  $Cq_{DNA}$  calculated by ValidPrime and RT(-) measurements. Fold ratios in linear scale ( $2^{-Cq(RT+)} / 2^{-Cq(RT-)}$ ) between either the total signal (NA) measured in spiked RT(+) reactions (dark bars) or the gDNA signal (DNA) estimated by ValidPrime (VP) from RT(+) reactions (light bars) compared to the signal in RT(-) reactions. A quantity of 20 ng of cDNA from adipose tissue (hatched bars) or from kidney, were spiked with 0.30 ng gDNA to decrease the variability due to stochastic amplification observed in RT(-) reactions. Independently of the expression level of the three genes studied in RT(+) samples, the estimations by ValidPrime of the gDNA-derived signals in RT(+) were very similar to the signals measured in RT(-) reactions, as the ratio was close to 1 (illustrated by the red dashed line; mean  $1.20 \pm 0.29$ ). Data are mean  $\pm$  SD from two experiments in duplicate on the StepOnePlus.

added to cDNA test samples with low, but detectable, endogenous gDNA levels. All 32 GOI assays were gDNA-sensitive (Supplementary Table S1) and had gDNA amplification efficiencies similar to the VPA (i.e. passed the ValidPrime high confidence criteria detailed in Supplementary Figure S3). Both the traditional StepOnePlus microtiter plate-based qPCR (Figure 3A) and the microfluidic BioMark system (7) (Figure 3B) were used to collect raw data ( $Cq_{NA}$ ) as input for ValidPrime estimations of the RNA-derived signal ( $Cq_{RNA}$ ). Samples were grouped according to the level of DNA contribution. Using ValidPrime, we could accurately estimate the RNA-derived signal ( $Cq_{RNA}$ ) even in samples with elevated gDNA-derived signals. However, the correction was less precise when the gDNA background exceeded 60% of the total signal. The demonstration that with ValidPrime we can identify and correct for signals derived from exogenous DNA in experimental RT-qPCR samples, using two different qPCR platforms, was first step toward a 'proof-of-principle'. The correction is virtually independent of gene copy number since it works well both for GOI assays targeting one single locus and for genes with multiple pseudogenes (Supplementary Figure S4).

### Correction of signals derived from endogenous gDNA


In order to evaluate the capacity of ValidPrime to correct for endogenous gDNA present in typical RNA preparations, a different strategy was applied. We used a gDNA-sensitive and a gDNA-insensitive assay for each GOI, with comparable amplification efficiencies. Three genes (*Illb*, *Serpine1* and *Chi3l3*) expressed in mouse macrophages were chosen as targets. Using the BioMark system, qPCR data were collected from 81 RNA

preparations and the ValidPrime correction was applied. Despite identical overall gDNA content, the impact of the gDNA on the total signal obtained with the gDNA-sensitive assays differed considerably between the three genes. When the impact was limited (i.e. low %DNA), as in the case for *Illb*, the effect of the ValidPrime correction was modest (Supplementary Figure S5). With increasing %DNA, as observed for *Serpine1* and *Chi3l3* (Figure 4A), the result of the correction becomes clearer, even in log2 scale (Figure 4B). Theoretically, given identical amplification efficiencies for the two assays and the absence of gDNA amplification, the  $Cq_{NA}$  data in the scatter plots in Figure 4B should fall on a straight line with a slope of 1. The presence of gDNA will contribute to the signal measured with gDNA sensitive assays (x-axis) and the uncorrected  $Cq_{NA}$  data will therefore produce a slope  $>1$ . Even though the impact of the correction differs for the three genes, the  $Cq_{RNA}$  values estimated using ValidPrime restore linearity, especially for samples with a DNA contribution  $<60\%$  (summarized in Figure 4C).

These data demonstrate that using ValidPrime, efficient correction of RT-qPCR data for the presence of endogenous gDNA is possible, as long as the DNA contribution to the total signal is  $<60\%$ .

### DISCUSSION

Since its invention in the early/mid 1990s (13,14), qPCR has undergone considerable methodological and technological advances (15). However, despite its direct impact on qPCR results, no alternative to RT(-) controls has, to our knowledge, been proposed to assess gDNA-derived contributions to the signals in RT-qPCR.



**Figure 3.** Correction of exogenous (spiked) gDNA with ValidPrime. The data are presented in linear scale as fold ratio ( $2^{-Cq}/2^{-Cq_{ref}}$ ), where  $Cq_{ref}$  is the  $Cq_{NA}$  measured on non-spiked controls and  $Cq$  refers to  $Cq_{RNA}$  (light bars) or  $Cq_{NA}$  (dark bars) depending on whether or not ValidPrime correction was applied (VP<sup>-</sup>/VP<sup>+</sup>). The data are grouped based on the impact of exogenous DNA, expressed as percentage of the total signal (%DNA) in each sample. Data were collected with either 17 GOI assays on a StepOnePlus (Applied Biosystems) using mVPA1 and mVPA5 (A), or with 19 assays on a BioMark (Fluidigm) using mVPA1 (B). All assays passed the high confidence ValidPrime criteria (Supplementary Figure S3). Data are presented as the mean  $\pm$  SD, with ( $n$ ) designating the number of samples in each group. cDNAs were from mouse kidney or liver for the StepOnePlus studies and mouse uterus for the BioMark study.

ValidPrime is a cost-efficient alternative to RT(-) controls to test for the presence of gDNA in samples. It is superior to RT(-) controls not only because of a higher accuracy, but also because fewer control reactions are required, eliminating the need for additional test reactions in the RT step. While the traditional approach for a study based on  $m$  samples and  $n$  genes requires  $m$  reverse transcription control reactions (RT-) and  $m \times n$  extra qPCRs, ValidPrime only requires  $m + n + 1$  control qPCRs and no RT(-) reactions (Table 1). As an example, in a BioMark 96.96 Dynamic Array experiment, ValidPrime reduces the number of controls by >95%.


ValidPrime is also the first method that proposes to correct for qPCR signals originating from contaminating gDNA. It is possible that the lack of accuracy and low reproducibility generally observed in RT(-) reactions has previously restrained the development of a correction-based model similar to that proposed in Equation (3). The present study includes data obtained with cDNA from five different mouse tissues analyzed with two qPCR instrument platforms, providing support for the general validity of ValidPrime.

It is important not to confuse gDNA contamination levels with the actual contribution of gDNA to the total signal, herein expressed as %DNA [Equation (6)]. Indeed, we did not observe any correlation between gDNA levels (as estimated by qPCR with the VPA) and the total signal ( $Cq_{NA}$ ) measured in RT(+) qPCR reactions with GOI assays (Supplementary Figure S6). However, as evidenced from the data shown in Figure 4A and Supplementary Figure S5A, there is a clear positive correlation between %DNA and  $Cq_{NA}$  with the gDNA sensitive assay, which demonstrates the increased impact of contaminating gDNA in samples with low GOI expression levels.

The primer design strategy also strongly influences the impact of gDNA on the qPCR signal. Given the multi-exonic nature of most eukaryotic genes (16), it is conceivable that gDNA-insensitive assays can be

designed for most targets in vertebrates. Regardless of the primer design strategy, the inability of a GOI assay to amplify gDNA needs to be validated experimentally. ValidPrime offers this possibility. However, for certain targets it is impossible to design transcript-specific assays. This can be due to either the presence of intronless pseudogenes or the absence of introns in single-exon genes. In order to assure a good accuracy for the ValidPrime correction, these gDNA sensitive assays should behave similarly to VPA against gDNA. In analogy with the comparative Ct method (or  $\Delta\Delta Ct$  method) (10), in which similar amplification efficiencies for the GOI and reference gene assays are presumed, estimation of  $Cq_{RNA}$  in ValidPrime assumes similar efficiencies for the GOI and gDNA assays.

When validated according to the Minimal Information for publication of Quantitative real-time PCR Experiments (MIQE) guidelines (17), gDNA-sensitive assays are in general perfectly compatible with ValidPrime. Nevertheless, when using a GOI assay for the first time with ValidPrime, and especially when  $Cq$  adjustment is requested, we recommend the inclusion of a gDNA dilution series with concentrations covering at least three  $\log_{10}$  (e.g. 5–5000 haploid genomic copies). Consistent relation to VPA across the dilution series indicates similar amplification efficiencies of the two assays, which sanctions  $Cq$  correction with high confidence (Supplementary Figure S3). For VPAs, as well as for high confidence GOI assays, we generally observed perfectly linear amplifications from 5 to 10000 haploid genomic copies (corresponding to 0.015–30 ng) (Supplementary Figures S2 and S3). Even though it is possible that higher gDNA concentrations (i.e. >30 ng per reaction) could influence qPCR amplification efficiencies (18), such gDNA contamination levels are rarely, if ever, encountered in RT-qPCR experiments. Furthermore, we did not observe any differences in the VPA amplification between samples with purified gDNA



**Figure 4.** Correction of endogenous gDNA with ValidPrime. Comparison of results obtained with two assays targeting *Serpine1* (left) or *Chi3l3* (right) in cDNA prepared from mouse peritoneal macrophages and measured in the BioMark qPCR system. The ‘gDNA-sensitive’ assays amplify both gDNA and cDNA, while the ‘gDNA-insensitive’ assays only recognize the transcript. (A) Scatter plots showing the correlation between the %DNA [as defined in Equation (6)] and  $Cq_{NA}$  data obtained with the gDNA-sensitive assays in each of 81 independent RNA preparations (means of duplicates). The positive correlation between %DNA and  $Cq$  illustrates the increasing impact of the gDNA contamination with decreasing total signal. Mean and median values refer to %DNA levels. (B)  $Cq_{NA}$  data measured with the gDNA-insensitive assays plotted against the corresponding  $Cq_{NA}$  data (dark blue) or ValidPrime-estimated  $Cq_{RNA}$  (light blue and orange), obtained with the gDNA-sensitive assays. Samples with a DNA contribution of 60–90 % are shown in orange and those with <60% in light blue. (C) Tables summarizing the effect of ValidPrime correction and data filtering on the slope and the coefficient of determination ( $R^2$ ).

and mixed samples, spiked with cDNA or RNA (Supplementary Table S2).

Even though we consistently observed very low variability between replicates in VPA-gDNA amplifications over a wide range of initial gDNA concentrations (Supplementary Figure S2 and Supplementary Table S2), it is advisable to use 1–10 ng gDNA (i.e.  $\approx 300$ –3000 haploid genome copies) per qPCR, when only one gDNA concentration is included in the design. This

range favors reliable and distinct gDNA amplification with the VPA and the ‘high confidence’ gDNA-sensitive GOI assays. It also increases the confidence when verifying the absence of gDNA amplification with GOI assays that are presumed to be ‘gDNA-insensitive’.

In this study, we used a maximal 0.3 SD for the  $\Delta Cq$  between VPA and GOI gDNA amplifications as criterion for high confidence gDNA-sensitive GOI assays. Alternatively, an efficiency ( $E$ ) based criterion can be

**Table 1.** ValidPrime reduces the number of required control reactions in RT-qPCR

No. of controls	Assays ( <i>n</i> )									
	1		10		24		48		96	
Samples ( <i>m</i> )										
1	2	3	11	<b>12</b>	25	<b>26</b>	49	<b>50</b>	97	<b>98</b>
10	20	<b>12</b>	110	<b>21</b>	250	<b>35</b>	490	<b>59</b>	970	<b>107</b>
24	48	<b>26</b>	264	<b>35</b>	600	<b>49</b>	1176	<b>73</b>	2328	<b>121</b>
48	96	<b>50</b>	528	<b>59</b>	1200	<b>73</b>	2352	<b>97</b>	4656	<b>145</b>
96	192	<b>98</b>	1056	<b>107</b>	2400	<b>121</b>	4704	<b>145</b>	9312	<b>193</b>

The roman values indicates Traditional RT- strategy:  $(m \times n) + m$  and the bold values indicates ValidPrime:  $(m + n + 1)$ . ValidPrime replaces the need to perform RT(-) controls for all RT(+) reactions and reduces substantially the number of controls compared to a conventional set up. In an expression profiling experiment based on *m* samples and *n* assays, the RT(-) approach requires *m* RT(-) reactions followed by  $m \times n$  qPCR controls, whereas ValidPrime only requires  $m + n + 1$  controls. The numbers in the table are based on single measurements for both approaches. Even when *p* gDNA samples/concentrations are included in the experimental setup using ValidPrime, the number of control reactions  $[m + (p \times n) + p]$  is still largely inferior to the RT(-) approach.

used. Indeed, similar results to those shown in Figure 3, were obtained when a maximal difference of 0.15 in *E* (defined as  $10^{-1/\text{slope}} - 1$ ) was used as inclusion criterion (data not shown). If a gDNA-sensitive GOI assay has a suboptimal, but confidently estimated *E* and cannot be replaced with a better assay, Equation (7) (19), or equivalent (20), can be used to correct the  $Cq_{\text{NA}}$ . Procedures for confident determination of amplification efficiencies are described elsewhere (21).

$$Cq_{\text{NA new}} = Cq_{\text{NA old}} \left( \frac{\log(1+E)}{\log(2)} \right) \quad (7)$$

Coherency of PCR product melting curve profiles from cDNA and gDNA samples should also be considered prior to  $Cq_{\text{RNA}}$  calculations. If a GOI assay generates gDNA-specific products that are not observed in cDNA samples,  $Cq_{\text{RNA}}$  adjustment of  $Cq_{\text{NA}}$  will not be reliable and is not recommended or even needed. Electrophoresis-based analysis of PCR-products is an alternative informative tool to verify that the same products are formed from cDNA and gDNA templates.

Caution should also be taken if differences in ploidy are expected, such as in cancer biopsies, since the number of VPA and GOI targets per cell could vary between samples. However, homogenous populations of aneuploid samples can be analyzed with ValidPrime, such as cancer cell lines, given that the VPA and GOI target loci are each present at least in one copy per cell.

To make ValidPrime readily available, we have developed a software application (gh-validprime) (H. L. and J. I., manuscript in preparation), that is free of charge for academic use. ValidPrime  $Cq_{\text{RNA}}$  calculation is also available within the data pre-processing workflow of the GenEx software (version 5.3, www.multid.se). The gh-validprime software assigns grades to assays/samples based on the impact of the genomic background (Supplementary Figure S7). The gDNA-insensitive

assays are classified as A+. Other assays are attributed the grades A, B, C and F, where the assignment is sample-dependent. While A (<3 %DNA) does not require correction, B and C samples (3–25 and 25–60 %DNA, respectively) are corrected, provided the assays pass the high confidence criteria. If gDNA contribution exceeds 60%, correction is not recommended. RT+ samples with gDNA concentrations below the limit of detection, in which the VPA fail to generate a signal, are attributed the grade A\*. The default output from the ValidPrime software is either  $Cq_{\text{NA}}$  (for A+ assays, A\* and A samples),  $Cq_{\text{RNA}}$  (for B and C samples) or 'HIGHDNA' for F samples. The output data are ready for further pre-processing, such as normalization against reference genes. The general ValidPrime workflow is summarized in Figure 5. The gDNA sensitivity and confidence evaluation of GOI assays can be performed independently, as outlined in Figure 5A, or together with RT(+) samples, which facilitates the specificity assessment. Figure 5B illustrates the flowchart for previously validated GOI assays.

The ValidPrime source code is available through the gh-validprime project at <https://code.google.com/p/gh-validprime>. This software depends on the Qt framework (<http://qt.nokia.com>) and the GeneHuggers library (<https://code.google.com/p/genehuggers>). A windows installer and test files are available at <http://code.google.com/p/gh-validprime/downloads/list>.

ValidPrime assays targeting different species (including human, mouse and a general vertebrate) have been developed by the TATAA Biocenter ([www.tataa.com](http://www.tataa.com)).

## CONCLUSION

ValidPrime provides, for the first time, the opportunity to correct reliably for gDNA background in qPCR. Correction is possible for any GOI assay that consistently amplifies gDNA, given that the DNA contribution does not exceed 60% of the signal. ValidPrime is superior to traditional RT(-) controls because of its higher accuracy and the lower number of controls required, which leads to a substantial cost savings.


## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online: Supplementary Tables 1 and 2, Supplementary Figures 1–7 and Supplementary References [1,10,17,22–25].

## ACKNOWLEDGEMENTS

The authors are grateful for critical comments from Drs Pascal Martin, Sébastien Déjean, Coralie Fontaine and Anders Ståhlberg. Drs Geneviève Tavernier and Elodie Riant provided mouse blood and tissue samples and Hortense Bergès provided technical assistance during the isolation of mouse macrophages.





**Figure 5.** ValidPrime flowchart. ValidPrime GOI assay validation. ValidPrime can be used as a reliable, cost-efficient alternative to RT(-) controls to survey gDNA background in RT-qPCR, and as a tool to determine the RNA-derived signal ( $Cq_{RNA}$ ) in RT(+)-qPCR reactions. To optimize its accuracy when  $Cq_{RNA}$  calculation is desired, validation of GOI assays in gDNA samples is recommended, as outlined in (A). Asterisks indicates the efficiency evaluation and melting curve/electrophoresis-based analysis. This includes an evaluation of the gDNA sensitivity of GOI assays using dilution series with gDNA samples spanning at least three  $\log_{10}$  in copy number. GOI assays that do not amplify gDNA are attributed the grade A+. The amplification of gDNA by high-confidence assays should be specific and with an efficiency similar to that of the VPA (see ‘Discussion’ section and Supplementary Figure S3). For GOI assays with suboptimal, but confidently determined (17,21) efficiency, Equation (7) could be applied to adjust  $Cq_{NA}$  data. To optimize specificity, there should also be consistency between the melting curves of PCR products in gDNA and cDNA samples. (B)  $Cq_{RNA}$  calculation with ValidPrime-validated GOI assays. High confidence and A+ assays can be used with less gDNA samples for  $Cq_{RNA}$  determination. It is recommended to confirm the absence of gDNA amplification at least once for A+ assays. Samples that do not contain sufficient gDNA to generate a signal with the VPA are attributed A\*. As for gDNA insensitive A+ assays,  $Cq_{RNA}$  equals  $Cq_{NA}$  (i.e. output = input) in A\* samples, since the DNA-derived signal is negligible [see Equations (2 and 4)]. For gDNA-sensitive GOI assays,  $Cq_{RNA}$  is calculated by a  $Cq_{DNA}$ -based correction of  $Cq_{NA}$  using Equations (4 and 5). To minimize the risk of jeopardizing the accuracy of the  $Cq_{RNA}$  estimation, it is not advisable to perform correction on samples where the DNA-derived signal exceeds 60%. The calculations are facilitated using the ValidPrime software. Details on additional assay/sample grading and data output formats employed by the software are provided in Supplementary Figure S7. The  $Cq_{RNA}$  output data can be used for downstream data processing, such as normalization against reference genes.

**FUNDING**

Institut National de la Santé et de la Recherche Médicale. Funding for the open access charge: Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France.

*Conflict of interest statement.* M.K. and D.S. are employees of TATAA Biocenter AB, a commercial source for the ValidPrime assays.

**REFERENCES**

- Bustin,S.A. (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. *J. Mol. Endocrinol.*, **29**, 23–39.
- Peccoud,J. and Jacob,C. (1996) Theoretical uncertainty of measurements using quantitative polymerase chain reaction. *Biophys. J.*, **71**, 101–108.
- Nordgård,O., Kvaloy,J.T., Farnen,R.K. and Heikkilä,R. (2006) Error propagation in relative real-time reverse transcription polymerase chain reaction quantification models: the balance between accuracy and precision. *Anal. Biochem.*, **356**, 182–193.
- Bengtsson,M., Hemberg,M., Rorsman,P. and Ståhlberg,A. (2008) Quantification of mRNA in single cells and modelling of RT-qPCR induced noise. *BMC Mol. Biol.*, **9**, 63.
- Calippe,B., Douin-Echinard,V., Laffargue,M., Laurell,H., Rana-Poussine,V., Pipy,B., Guery,J.C., Bayard,F., Arnal,J.F. and Gourdy,P. (2008) Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. *J. Immunol.*, **180**, 7980–7988.
- Hofstetter,J.R., Zhang,A., Mayeda,A.R., Guscar,T., Nurnberger,J.I. Jr and Lahiri,D.K. (1997) Genomic DNA from mice: a comparison of recovery methods and tissue sources. *Biochem. Mol. Med.*, **62**, 197–202.
- Spurgeon,S.L., Jones,R.C. and Ramakrishnan,R. (2008) High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. *PLoS One*, **3**, e1662.
- Riant,E., Waget,A., Cogo,H., Arnal,J.F., Burcelin,R. and Gourdy,P. (2009) Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. *Endocrinology*, **150**, 2109–2117.
- Giulietti,A., Overbergh,L., Valckx,D., Decallonne,B., Bouillon,R. and Mathieu,C. (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. *Methods*, **25**, 386–401.
- Livak,K.J. and Schmittgen,T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*, **25**, 402–408.
- Bustin,S.A. and Nolan,T. (2004) Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. *J. Biomol. Tech.*, **15**, 155–166.
- Nolan,T., Hands,R.E. and Bustin,S.A. (2006) Quantification of mRNA using real-time RT-PCR. *Nat. Protoc.*, **1**, 1559–1582.
- Higuchi,R., Fockler,C., Dollinger,G. and Watson,R. (1993) Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. *Biotechnology*, **11**, 1026–1030.
- Gibson,U.E., Heid,C.A. and Williams,P.M. (1996) A novel method for real time quantitative RT-PCR. *Genome Res.*, **6**, 995–1001.
- Pfaffl,M.W. (2010) The ongoing evolution of qPCR. *Methods*, **50**, 215–216.
- Roy,S.W. and Gilbert,W. (2006) The evolution of spliceosomal introns: patterns, puzzles and progress. *Nat. Rev. Genet.*, **7**, 211–221.
- Bustin,S.A., Benes,V., Garson,J.A., Hellemans,J., Huggett,J., Kubista,M., Mueller,R., Nolan,T., Pfaffl,M.W., Shipley,G.L. *et al.* (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin. Chem.*, **55**, 611–622.
- Yun,J.J., Heisler,L.E., Hwang,I.I.L., Wilkins,O., Lau,S.K., Hyrcza,M., Jayabalasingham,B., Jin,J., McLaurin,J., Tsao,M.S. *et al.* (2006) Genomic DNA functions as a universal external standard in quantitative real-time PCR. *Nucleic Acids Res.*, **34**, e85.
- Kubista,M., Sindelka,R., Tichopad,A., Bergkvist,A., Lindh,D. and Forootan,A. (2007) The Prime Technique. Real-time PCR data analysis. *GIT Lab. J.*, **9–10**, 33–35.
- Pfaffl,M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.*, **29**, e45.
- Tholen,D.W., Kroll,M., Astles,J.R., Caffo,A.L., Happe,T.M., Krouwer,J. and Lasky,F. (2003) *Evaluation of the Linearity of Quantitative Measurement Procedures: a Statistical Approach; Approved Guideline*, Vol. 23, CLSI EP6-A. Clinical and Laboratory Standards Institute, Wayne, PA, pp. 1–60.
- Vandesompele,J., De Preter,K., Pattyn,F., Poppe,B., Van Roy,N., De Paepe,A. and Speleman,F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.*, **3**, RESEARCH0034.
- Andersen,C.L., Jensen,J.L. and Orntoft,T.F. (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res.*, **64**, 5245–5250.
- Hellemans,J., Mortier,G., De Paepe,A., Speleman,F. and Vandesompele,J. (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. *Genome Biol.*, **8**, R19.
- Liu,Y.J., Zheng,D., Balasubramanian,S., Carriero,N., Khurana,E., Robilotto,R. and Gerstein,M.B. (2009) Comprehensive analysis of the pseudogenes of glycolytic enzymes in vertebrates: the anomalously high number of GAPDH pseudogenes highlights a recent burst of retrotranspositional activity. *BMC Genomics*, **10**, 480.

# Supplementary Information – Laurell *et al.*

- Supplementary Tables S1-S2
  - S1: GOI and VPA primer sequence information
  - S2: VPA amplification is equivalent when using pure gDNA and mixed samples
- Supplementary Figures S1-S7
  - S1A: Derivation of  $Cq_{\text{RNA}}$  formula
  - S1B: Comparison between ValidPrime  $Cq_{\text{DNA}}$  determination and the  $\Delta\Delta\text{Ct}$  method.
  - S2: Determination of VPA LOD and LOQ
  - S3: Confidence evaluation of GOI assays
  - S4: ValidPrime with GOIs targeting one or multiple genomic loci
  - S5: Effect of ValidPrime  $Cq_{\text{RNA}}$  correction on samples with low gDNA derived signal (%DNA)
  - S6: Absence of correlation between gDNA levels and GOI expression
  - S7: ValidPrime GOI assay validation and grading

GOI Symbol	Forward	Reverse	Amplicon length	UCSC Gene Reference
High confidence GOI assays used in the StepOneplus qPCR system				
<i>Ccl2</i>	TTCAGCACCTTTGAATGTGAAGTT	TGCTTGAGGTGGTTGTGGAA	80	uc007kmp.1__Ccl2:418+497
<i>Cebpa</i>	AGGGACTTAGGTGTTGGGGATT	GTGCAAAAAGCAAGGGATTAGG	87	uc009gjl.1__Cebpa:1712+1798
<i>Ch25h</i>	GTGATTAACATCTGGCTGTCCG	AAAGGGCACAAGTCTGTGAGTG	78	uc008hgj.1__Ch25h:622+699
<i>Fdx1</i>	CGGAGCAGCTCAGAAGATAAGAT	CAATTTTCCCCTTGTCGTTAG	79	uc009plo.1__Fdx1:256+334
<i>Gapdh</i> Tataa	Included in the mouse reference gene panel (Tataa biocenter)			
<i>Plat</i>	TATTGTCGGAATCCAGATGGTG	GCATGGGGACATGTCACAGTAT	93	uc009ldx.2__Plat:900+992
<i>Ppia</i>	GAGCTGTTTGCAGACAAAGTTC	CCCTGGCACATGAATCCTGG	125	uc007hyn.1__Ppia:108+232
<i>Ppia</i> Tataa	Included in the mouse reference gene panel (Tataa biocenter)			
<i>Ptgs1</i>	CCAGAACCAGGGTGTCTGTGT	GTAGCCCGTGCAGTACAATC	70	uc008jll.1__Ptgs1:266+335
<i>Retnla</i>	CCAATCCAGCTAACTATCCCTCC	GGAGGCCCATCTGTTTCATAGTC	80	uc007zjv.1__Retnla:221+300
<i>Rhoa</i>	TGCATCTGAGAAGTTCCAGGTACT	ACCACAAGTCCATCACCAAC	125	uc009rpe.2__Rhoa:353+477
<i>Serpine1</i>	ACAGCCTTTGTCATCTCAGCC	CCGAACCACAAAGAGAAAGGA	75	uc009abn.2__Serpine1:1229+1303
<i>Vcam1</i>	CATGGAGCCTGTCAATTTGAG	GGGAAAGAGTAGATGTCCACG	106	uc008rbx.1__Vcam1:564+669
High confidence GOI assays used in the Biomark system				
<i>Cebpb</i>	CAAACGTGGCTGAGCGCTG	TACTCAGGGCCCGGCTGACA	72	uc008oaf.1__Cebpb:1210+1281
<i>Ctsf</i>	TGCCCGCCTGAATGGGACT	CTGGCCCTCCACGTTGCTG	112	uc008gbc.1__Ctsf:883+994
<i>Cyr61</i>	ACGGCTGCGGCTGCTGTAAG	GGTGGAGCTGGCGCCGAAAT	113	uc008rqq.2__Cyr61:336+448
<i>Id1</i>	ACAGCGGGCGAGGTGGTACT	TGCTGCTCGTCCAGCAAGGC	95	uc008ngf.1__Id1:134+228
<i>Ier2</i>	TGCTGGTGCAGCTGTGGTG	TTCGCCTCGGCTGTGCGTTC	90	uc009mmr.2__Ier2:739+828
<i>Igfbp5</i>	AGAAAGCAGTGTAAGCCCTCCC	CCGGCAGCTTATTCCGTAATT	79	uc007bxx.1__Igfbp5:1402+1480
<i>Ipo5</i>	CCTCTTCTCTCTCACGCCTAGC	AGCAGGTTTCCAGGAGCAGGTA	84	uc007uzz.1__Ipo5:33+116
<i>Junb</i>	GAAGCGGAAGCTGGAGCGCA	GCTCCCGTAGGAGACCGCA	101	uc012ghn.1__Junb:1138+1238
<i>Mad2l1</i>	GAGAGGCAGGGAGGACAGCTT	CCTCGTTTCAGGCACCACAAA	120	uc009cen.1__Mad2l1:1096+1215
<i>Nfkbia</i>	CTGTGAGCAGGGCTGCCTGG	GTGGCCTGCAGGACGGAGTG	84	uc007nor.2__Nfkbia:574+657
<i>Pik3r2</i>	TGAGTCAGGCCACATACTCCA	AGCTCTGCTTGCTCAATGGCTT	105	uc009mbn.2__Pik3r2:796+900
<i>Rasd1</i>	ACGACCCTCAGCGTTGTGCC	TGGCCATGGCAAAGAGCGCA	90	uc007jfh.1__Rasd1:634+723
<i>Sox4</i>	TGGCCACCCAGCCAAACAC	CGAAGCGCCAGGCTTCCAA	74	uc007pyk.1__Sox4:1407+1480
<i>Sprr2f</i>	CAAGCAACCTGCCAGCCTCC	AGGCTCAGGGCACACCGAGG	82	uc008qdu.1__Sprr2f:86+167
<i>Ubb</i>	TGGCCGACCTCTCTGATT	GATGCCACCTCTCAGGCGA	77	uc007jjg.1__Ubb:254+330
High confidence GOI assays used in both qPCR systems				
<i>Gapdh</i>	AGGTCGGTGTGAACGGATTG	TGTAGACCATGTAGTTGAGGTCA	123	uc009dts.1__Gapdh:58+180
<i>Mapk3</i>	TCAGAGCGCCACCCTGGAA	TGAGGCCCGGAGGATCTGG	144	uc009jsm.1__Mapk3:343+486
<i>Odc1</i>	TCGACCTTGTGAGGAGCTGGTGA	GGATGTGGCAGTCAAACCTGTC	108	uc007ncv.1__Odc1:343+450
<i>Tgfb3</i>	GCAAGAATCTGCCACAAGG	CACTCGCGCACAGTGTCACT	69	uc007ohn.2__Tgfb3:1672+1741
GOI assays used in the Biomark for correction of endogenous DNA				
<i>I11b gDNA A+</i>	CAACCAACAAGTGATATTCTCCATG	GATCCACTCTCCAGCTGCA	152	uc008mht.1__I11b:527+678
<i>I11b gDNA</i>	TGAAGAAGAGCCCATCCTCTGT	GCAGGTTATCATCATCCCA	50	uc008mht.1__I11b:359+408
<i>Serpine1 A+</i>	ACAAGTCTTCCGACCAAGAGC	TCGTTTACTCGATCCTGACCT	71	uc009abn.2__Serpine1:1133+1203
<i>Serpine1</i>	ACAGCCTTTGTCATCTCAGCC	CCGAACCACAAAGAGAAAGGA	75	uc009abn.2__Serpine1:1229+1303
<i>Chi3l3 A+</i>	GAAGCCCTCCTAAGGACAAACA	GCCTTGAATGTCTTCTCCAC	96	uc008qvw.2__Chi3l3:480+575
<i>Chi3l3</i>	AGAAGGGAGTTTCAAACCTGGT	GTCTTGCTCATGTGTGAAGTGA	109	uc008qvw.2__Chi3l3:154+262
VPAs used in the study				
mVPA1	GGAGCCAGTGTAGAAGAGCA	AGCCAGCGAACCATATCCTGA	87	chr1:41857082+41857168
mVPA5	ACAGGAGAGCCACGTGTATCC	ACTCCCTGTTCTTGACGTGCT	111	chr5:117408738+117408848

### Supplementary Table S1.

**Primer sequence information for GOI assays and VPAs.** A+ indicates primers that do not amplify gDNA. UCSC references refer to sequence coordinates in the genome browser at UCSC (<http://genome.ucsc.edu>) according to the NCBI37/mm9 assembly.

Spiking Source	Description	gDNA copy#	Mean Cq (VPA)	SD (n=4)	slope	VPA Efficiency (%)	R <sup>2</sup>
Adipose Tissue	DNase treated cDNA	0	ND				
		50	30.46	0.02	-3.267	102.3	0.9997
		200	28.55	0.18			
		1000	26.21	0.06			
0	ND						
Adipose Tissue	DNase treated RNA	50	30.42	0.36	-3.365	98.2	0.9999
		200	28.43	0.25			
		1000	26.05	0.08			
		0	ND				
Liver	DNase treated cDNA	50	30.33	0.06	-3.378	97.7	0.9994
		200	28.39	0.07			
		1000	25.94	0.09			
		0	ND				
Liver	DNase treated RNA	50	30.51	0.23	-3.397	96.9	0.9993
		200	28.57	0.12			
		1000	26.1	0.07			
		0	ND				
Yeast	tRNA	50	30.26	0.34	-3.303	100.8	0.9982
		200	28.1	0.09			
		1000	25.95	0.05			
		0	ND				
H <sub>2</sub> O	H <sub>2</sub> O	50	30.26	0.28	-3.359	98.5	0.9978
		200	28.42	0.18			
		1000	25.9	0.06			
		0	ND				
					Mean	99.2	0.9993
					SD	2.3	0.0007
		gDNA copy#	CV (%) (n=24)				
		50	16.26				
		200	14.52				
		1000	8.51				

### Supplementary Table S2.

#### Presence of cDNA or RNA does not affect the quantification of gDNA with VPA.

Addition of 20 ng of cDNA (DNase treated), RNA (DNase treated) or tRNA to different amounts of gDNA (0.15, 0.6, 3.0 ng corresponding to 50, 200, 1000 haploid genome copies) did not affect the amplification efficiency (expressed in %) of mVPA1 (n=4/condition). A one-way ANOVA analysis (Tukey-Kramer, GenEx v.5.3) did not reveal any significant difference between the groups with same gDNA concentration. Indeed, the coefficient of variation (CV), calculated on relative quantities (), of all 24 data points (=6\*4) for each gDNA concentration was less than 20%. Furthermore; the absence of signal (ND) in all samples with no gDNA demonstrates that there is no transcriptional activity at the VPA locus.

## Supplementary Figure S1A

$$(S1) \quad N_{Cq_{DNA}} = N_{DNA}^0 2^{Cq_{DNA}}$$

$$(S2) \quad N_{Cq_{RNA}} = N_{RNA}^0 2^{Cq_{RNA}-1}$$

$$(S3) \quad N_{NA} = N_{DNA} + N_{RNA}$$

$$(S4) \quad N_{Cq_{NA}} = N_{DNA}^0 2^{Cq_{NA}} + N_{RNA}^0 2^{Cq_{NA}-1}$$

$$(S5) \quad N_{Cq_{NA}} = N_{Cq_{DNA}} = N_{Cq_{RNA}}$$

$$(S6) \quad N_{DNA}^0 2^{Cq_{DNA}} = N_{DNA}^0 2^{Cq_{NA}} + N_{RNA}^0 2^{Cq_{NA}-1}$$

$$(S7) \quad N_{RNA}^0 2^{Cq_{RNA}-1} = N_{DNA}^0 2^{Cq_{NA}} + N_{RNA}^0 2^{Cq_{NA}-1}$$

$$(S8) \quad N_{RNA}^0 2^{Cq_{NA}-1} = N_{DNA}^0 (2^{Cq_{DNA}} - 2^{Cq_{NA}})$$

$$(S9) \quad N_{RNA}^0 (2^{Cq_{RNA}-1} - 2^{Cq_{NA}-1}) = N_{DNA}^0 2^{Cq_{NA}}$$

$$(S10) \quad \frac{2^{Cq_{RNA}-1} - 2^{Cq_{NA}-1}}{2^{Cq_{NA}-1}} = \frac{2^{Cq_{NA}}}{2^{Cq_{DNA}} - 2^{Cq_{NA}}}$$

$$(S11) \quad 2^{Cq_{RNA}-1} = \frac{2^{2Cq_{NA}-1}}{2^{Cq_{DNA}} - 2^{Cq_{NA}}} + 2^{Cq_{NA}-1}$$

$$(S12) \quad Cq_{RNA} = 1 + \log_2 \left( \frac{2^{2Cq_{NA}-1}}{2^{Cq_{DNA}} - 2^{Cq_{NA}}} + 2^{Cq_{NA}-1} \right)$$

$$(S13) \quad Cq_{RNA} = 1 + \log_2 \left( \frac{2^{Cq_{DNA}+Cq_{NA}-1}}{2^{Cq_{DNA}} - 2^{Cq_{NA}}} \right)$$

$$(S14) \quad Cq_{RNA} = Cq_{DNA} + Cq_{NA} - \log_2 (2^{Cq_{DNA}} - 2^{Cq_{NA}})$$

$$(S15) \quad Cq_{RNA} = -\log_2 (2^{-Cq_{NA}} - 2^{-Cq_{DNA}})$$

### Derivation of Cq<sub>RNA</sub>

Double stranded DNA provides twice the number of template molecules for PCR amplification compared to single stranded cDNA produced from RNA (S1, S2). We define the number of nucleic acid (NA) molecules in a sample as the sum of the number of dsDNA and single stranded cDNAs produced from RNA (S3, S4). At threshold the number of molecules in the test tube is the same regardless of whether or not the template was double or single stranded (S5). This gives a relation between Cq<sub>DNA</sub> (measured in a PCR sensing only the DNA component), Cq<sub>RNA</sub> (measured in a PCR sensing only the RNA component) and Cq<sub>NA</sub> (measured in a PCR sensing both nucleic acids) (S6, S7). After rearrangement (S8, S9) the two equations are combined to eliminate starting amounts (S10). After further arrangements (S11-S15) Cq<sub>RNA</sub> is expressed as function of the measured Cq<sub>NA</sub> and Cq<sub>DNA</sub> (measured either directly by a RT(-)-qPCR or indirectly using the more sensitive ValidPrime assay), which is used in equation 4 in Figure 1 of the main text. The derivation above assumes 100 % PCR efficiency.

## Supplementary Figure S1B

$$(S16) \quad (Cq_{Sample}^{GOI} - Cq_{Sample}^{RG}) - (Cq_{Calibrator}^{GOI} - Cq_{Calibrator}^{RG}) = \Delta\Delta Ct$$

$$(5) \quad Cq_{DNA} = Cq_{Sample}^{VPA} + Cq_{gDNA}^{GOI} - Cq_{gDNA}^{VPA}$$

$$(S17) \quad Cq_{DNA} - Cq_{Sample}^{VPA} = Cq_{gDNA}^{GOI} - Cq_{gDNA}^{VPA}$$

$$(S18) \quad (Cq_{DNA} - Cq_{Sample}^{VPA}) - (Cq_{gDNA}^{GOI} - Cq_{gDNA}^{VPA}) = \Delta\Delta Cq = 0$$

### *Comparison between ValidPrime $Cq_{DNA}$ determination and the $\Delta\Delta Ct$ method.*

Being based on the addition and subtraction of Cq values, the calculation of  $Cq_{DNA}$  by ValidPrime has a certain resemblance with the  $\Delta\Delta Ct$  equation (Equation S16) proposed by Livak and Schmittgen (10). The  $\Delta\Delta Ct$  method was the first to propose a mean for normalization of qPCR data of a GOI (or target) against a reference gene (RG) and a calibrator (control) sample. It was later further developed to include the use of multiple reference genes (22-24). The resemblance with the  $Cq_{DNA}$  determination in ValidPrime is more clearly appreciated in the rearrangement of Equation 5 into Equations S17 and S18. In ValidPrime, the gDNA can thus be considered as the calibrator sample and the ValidPrime assay (VPA) as the reference gene. As in the  $\Delta\Delta Ct$  method, in which similar amplification efficiencies for the GOI and RG assays are presumed, ValidPrime assumes similar efficiencies for the VPA and the GOI assays in order to correctly estimate  $Cq_{DNA}$  and consequently  $Cq_{RNA}$ . However, in contrast to the  $\Delta\Delta Ct$  method, in which all four terms are experimentally determined, the result of equation S18 always equals zero<sup>(\*)</sup>, since the  $Cq_{DNA}$  is unknown and defined by the other 3 Cq values in the equation. Furthermore, the aim of the “normalization” is clearly different. In ValidPrime the inclusion of gDNA serves as reference to evaluate gDNA-sensitivity of GOI assays compared to the VPA. Thus, despite the resemblance, the two methods are distinct and not interchangeable.

(\*) Implementation of equation S18 on the data shown in Figure 2 with the replacement of  $Cq_{DNA}$  with the RT(-) data, generated indeed a result close to zero : 0.14+/-0.35 (n=24) (mean+/-SD).

10. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*, **25**, 402-408.

22. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A. and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol*, **3**, RESEARCH0034.

23. Andersen, C.L., Jensen, J.L. and Orntoft, T.F. (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res.*, **64**, 5245-5250.

24. Hellems, J., Mortier, G., De Paepe, A., Speleman, F. and Vandesompele, J. (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. *Genome Biol*, **8**, R19.



# Supplementary Figure S2

Limit of detection (LOD) and Limit of quantification (LOQ) of ValidPrime assay mVPA1

Quantities (genome copies)	Mean Cq	SD (Cq)	Number of calls (of 6)
0	NA	NA	0
1	35.26	1.148	5 (5)
2	34.36	0.687	5 (5)
4	33.51	0.346	6 (5)
8	32.82	0.343	6 (5)
16	31.73	0.366	6 (6)
32	30.56	0.179	6 (5)
64	29.79	0.200	6 (6)

Quantities (#copies)	slope	efficiency (%)	R <sup>2</sup>
1-64	-3.080	111.2	0.994
2-64	-3.159	107.3	0.993
4-64	-3.336	99.4	0.996
8-64	-3.416	96.2	0.993

Genex LOD	Copy number
Cut-Off Cq: 36	3.69
Cut-Off Cq: 37	3.89
	(95%CI)




## Capacity of mVPA1 to amplify low copy number templates. Determination of LOD and LOQ.

Different concentrations of gDNA (from 0 to 64 haploid genome copies) were used as template in qPCR reactions with the mVPA1 assay. The melting curve analysis includes all positive calls (n=40). Limit of detection (LOD) and PCR efficiency were determined with GenEx software and the limit of quantification (LOQ) was defined using  $SD < 0.45$  as the upper limit of precision. Taking the concentrations above LOD into account the PCR efficiency (E) was estimated to:  $1.00 \pm 0.16$  (95% CI). Similar results were obtained with the mVPA5 assay as well as with higher gDNA concentrations (see Supplementary Table 2 and Material and Methods section).



## Supplementary Figure S3




*ValidPrime* correction is more reliable after GOI assay validation using gDNA dilution series. For certain target genes it is impossible to design gDNA-insensitive assays. This could be due to the presence of well-conserved pseudogenes (eg. *Gapdh* (A)) or the absence of introns (eg. *Ier2* (B)). When validated according to the MIQE guidelines (17) gDNA-sensitive assays are normally perfectly compatible with *ValidPrime*. Nonetheless, we recommend using a dilution series of four or more reference gDNA concentrations in the initial validation of a GOI assay with *ValidPrime*. This does not replace the established criteria for assay validation, but specifically aims to ensure that assays do not behave unexpectedly when purified gDNA is used as template. To obtain accurate estimates of gDNA background contributions, the GOI and the VPA amplification efficiencies should be similar, which is the case if the slopes of the standard curves are the same. Consequently, the distance between the curves ( $\Delta Cq$  in panel a) is similar at all gDNA concentrations. Based on the training data sets obtained with two different qPCR technologies, we found 0.3 as maximal standard deviation (SD) of the  $\Delta Cq$ s between GOI and VPA appropriate to assign a high confidence level to the GOI assay used for *ValidPrime* correction. The data shown were generated on the Biomark instrument.


17. Bustin, S.A., Benes, V., Garson, J.A., Hellems, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M.W., Shipley, G.L., Vandesompele, J. and Wittwer C.T. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin. Chem.*, **55**, 611-622.

# Supplementary Figure S4

A.



B.




*ValidPrime applied on targets with one or multiple genomic loci.*

cDNA samples were spiked with gDNA and analyzed with or without Validprime. Uncorrected ratios of relative quantities (left) and ValidPrime corrected ratios (right) are shown as mean  $\pm$  SD relative to the unspiked control. gDNA background contribution is indicated under the bars. **(A)** Data were generated with assays for *Ch25h*, *Serpine1* and *Tgfb3*, which all target a single locus. 88 samples were analyzed. **(B)** Using an assay targeting *Gapdh*, which has more than 50 well-conserved intronless pseudogenes in vertebrates and more than 300 in rodents (25), only 1 out of 25 samples spiked with up to 3000 genome copies had more than 60% DNA contribution as consequence of high *Gapdh* expression. Experiments were performed on the StepOnePlus.

25. Liu, Y.J., Zheng, D., Balasubramanian, S., Carriero, N., Khurana, E., Robilotto, R. and Gerstein, M.B. (2009) Comprehensive analysis of the pseudogenes of glycolytic enzymes in vertebrates: the anomalously high number of GAPDH pseudogenes highlights a recent burst of retrotrans-positional activity. *BMC Genomics*, **10**, 480.


# Supplementary Figure S5



*The effect of ValidPrime correction is modest when the contribution of endogenous gDNA on the total signal is low.*

Similar experiment as described in Figure 4, with gDNA sensitive and insensitive assays targeting *Il1b*. Data are from cDNAs obtained from mouse peritoneal macrophages, treated or not with LPS, and measured by qPCR on the Biomark. The gDNA sensitive assay passed the high confidence criteria for gDNA amplification (Supplementary Figure S3). Data are from 81 independent RNA preparations (mean of duplicates). **(A)** Scatter plot showing the correlation between %DNA (*ie the gDNA derived signal as fraction of the total signal expressed in relative quantities (Equation 6)*) and Cq<sub>NA</sub> measured with gDNA sensitive assay. Mean and median values refer to %DNA levels. **(B)** Cq data obtained with the 2 assays, either as Cq<sub>NA</sub> shown in dark blue or as ValidPrime corrected Cq<sub>RNA</sub> in light blue. **(C)** Table summarizing the effect of ValidPrime correction on the slope and the coefficient of determination (R<sup>2</sup>) of logarithmic (Cq) data. **(D)** The impact of ValidPrime correction becomes more evident in the linear scale. Same data as in (B) but presented as inversed relative quantities. **(E)** Summary of the linear regression analyses on data in (D), illustrating more clearly the positive effect of ValidPrime on linearity.

## Supplementary Figure S6




### *Absence of correlation between gDNA levels and GOI expression levels.*

Data from the experiment described in Figure 4 and Supplementary Figure 5, but with gDNA levels (as measured by VPA qPCR) plotted against the raw signal ( $Cq_{NA}$ ) obtained with gDNA sensitive assays targeting *Il1b*, *Serpine1* or *Chi3l3*. Data are from 81 cDNAs obtained from mouse peritoneal macrophages, treated or not with LPS *ex vivo*, and measured by qPCR on the Biomark. The relatively large dispersion of gDNA levels between samples (up to 4.5 Cq difference) is coherent with previous findings in the literature (1).

1. Bustin, S.A. (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. *J. Mol. Endocrinol.*, **29**, 23-39.

## Supplementary Figure S7

### A. ValidPrime GOI assay validation : $\geq 4$ gDNA conc



### B. ValidPrime-validated GOI assays : 1 - 3 gDNA conc

Grade	%DNA	VP correction	OutPut Data/Flags		
			High Conf Assay	A+ assays	
A+	ND	-	Cq <sub>NA</sub>	-	} Sample independent
A	<3 %	NO	-	Cq <sub>NA</sub>	
B	3-25 %	YES	-	Cq <sub>RNA</sub>	} Sample dependent
C	25-60 %	YES	-	Cq <sub>RNA</sub>	
F	>60 %	NO	-	HIGHDNA	

#### ValidPrime GOI assay validation and grading.

(a) An initial screening with a gDNA dilution series serves two purposes: 1) A robust identification of gDNA insensitive (A+) assays; 2) The classification of GOI assays amplifying gDNA. High confidence assays should amplify gDNA over the entire range of gDNA concentrations, with an estimated efficiency close to that of the VPA (Supplementary Figure S3). The gh-validprime software (<https://code.google.com/p/gh-validprime>) attributes grades A,B,C and F to the gDNA sensitive assays depending on the DNA contribution in each qPCR reaction according to the table. (b) Once an assay has been appropriately tested in ValidPrime, High confidence assays and A+ assays can be used with a reduced number of gDNA samples. The table summaries the nature of the default output from the gh-validprime software, which can be used for further pre-analytic data processing.